Cetuximab - Eli Lilly

Drug Profile

Cetuximab - Eli Lilly

Alternative Names: Anti-EGFR monoclonal antibody 225; C 225; ch 225; Erbitux; IMC-C225; LY-2939777

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California System
  • Developer Array BioPharma; Bristol-Myers Squibb; Celldex Therapeutics Inc; Centre Jean Perrin; Eli Lilly; Merck KGaA; New York University School of Medicine; Novartis; Pierre Fabre; Roche; University Hospital Ghent; University of Heidelberg; University of Michigan Comprehensive Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Head and neck cancer
  • Phase III Non-small cell lung cancer
  • Phase II Bladder cancer; Breast cancer; Gastric cancer; Mesothelioma; Rectal cancer
  • Phase I/II Adenoid-cystic-carcinoma
  • Phase Unknown Oesophageal cancer
  • No development reported Pancreatic cancer; Prostate cancer

Most Recent Events

  • 31 Aug 2018 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Combination therapy, Recurrent, Metastatic disease) in Spain, Hungary (IV) (EudraCT2018-001529-24)
  • 16 Aug 2018 Bristol-Myers Squibb completes a phase II trial in Head and neck cancer (First line therapy, Metastatic disease, Combination therapy) in USA (NCT01218048)
  • 08 Aug 2018 Celldex plans to complete enrolment in the first stage of its phase II trial for Head and neck cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (NCT03254927)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top